IM-250

IM-250
Names
IUPAC name
(S)-2-[4-(2,5-difluorophenyl)phenyl]-N-methyl-N-[4-methyl-5-(methylsulfonimidoyl)-1,3-thiazol-2-yl]acetamide
Identifiers
3D model (JSmol)
ChemSpider
  • InChI=1S/C20H19F2N3O2S2/c1-12-19(29(3,23)27)28-20(24-12)25(2)18(26)10-13-4-6-14(7-5-13)16-11-15(21)8-9-17(16)22/h4-9,11,23H,10H2,1-3H3
    Key: JDZTWDISDHLKCR-UHFFFAOYSA-N
  • CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=C(C=CC(=C3)F)F)S(=N)(=O)C
Properties
C20H19F2N3O2S2
Molar mass 435.51 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

IM-250 (Adibelivir) is an anti-herpetic drug candidate[1] developed by Innovative Molecules Gmbh.[2] The drug was conceived by a chemist at the company, who hypothesized that swapping the sulfonamide functional group of pritelivir for a sulfoximine would reduce off-target effects. In addition, the pyridine ring on pritelivir was changed to a 2,5-difluorobenzene ring to make the drug candidate more likely to enter the central nervous system as herpes can lie dormant within neurons.[3]

Innovative Molecules raised 20 million euro for clinical trials on humans.[4]

Clinical Development

In June 2023, Innovative Molecules announced that the first subjects had been dosed in a German Phase 1 clinical trial of IM-250.[5][6]

By January 2026, the company announced completion of its Phase 1 clinical development program and advancement into Phase 2 clinical testing for recurrent genital herpes.[7]

Mechanism of Action

IM-250 is a helicase-primase inhibitor[8], which interferes with viral DNA replication.

Partnerships and Licensing

In January 2026, Innovative Molecules entered a strategic licensing agreement with Italian pharmaceutical company Alfasigma for development of a parenteral formulation of IM-250, for the treatment of HSV Encephalitis.[9]

See also

References

  1. ^ Gege, Christian; Bravo, Fernando J.; Uhlig, Nadja; Hagmaier, Timo; Schmachtenberg, Rosanne; Elis, Julia; Burger-Kentischer, Anke; Finkelmeier, Doris; Hamprecht, Klaus; Grunwald, Thomas; Bernstein, David I.; Kleymann, Gerald (16 June 2021). "A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections". Science Translational Medicine. 13 (598) eabf8668. doi:10.1126/scitranslmed.abf8668. PMID 34135112.
  2. ^ "Drug Candidate Shows 'Potent Anti-Herpes Activity'". 17 June 2021.
  3. ^ "Small molecule fights active and latent herpes infections in rodents". 21 January 2025.
  4. ^ Lücking, Ulrich (7 October 2022). "New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective". Chemistry – A European Journal. 28 (56) e202201993. Bibcode:2022ChEuJ..28E1993L. doi:10.1002/chem.202201993. PMID 35789054.
  5. ^ "Innovative Molecules Announces First Subjects Dosed in the German Phase 1 Clinical Trial of IM-250 - Innovative Molecules". www.innovativemolecules.com. Retrieved 2026-05-10.
  6. ^ Innovative Molecules GmbH (2024-10-22). Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of IM-250 in Healthy Volunteers (Report). clinicaltrials.gov.
  7. ^ "Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir - Innovative Molecules". www.innovativemolecules.com. Retrieved 2026-05-10.
  8. ^ Gege, Christian; Bravo, Fernando J.; Uhlig, Nadja; Hagmaier, Timo; Schmachtenberg, Rosanne; Elis, Julia; Burger-Kentischer, Anke; Finkelmeier, Doris; Hamprecht, Klaus; Grunwald, Thomas; Bernstein, David I.; Kleymann, Gerald (2021-06-16). "A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections". Science Translational Medicine. 13 (598) eabf8668. doi:10.1126/scitranslmed.abf8668. ISSN 1946-6242. PMID 34135112.
  9. ^ Kääb, Georg (2026-01-15). "Munich's Innovative Molecules signs €125M partnership with Alfasigma to advance HSV encephalitis antiviral". European Biotechnology Magazine. Retrieved 2026-05-10.


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.